Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET study of alternating lutetium-177 PSMA therapy and radium-223 in oligometastatic hormone-sensitive prostate cancer
NL-OMON59548Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan and radium-223 dichloride in prostate cancer (PCa), sponsored by Amsterdam University Medical Center. Primary endpoint: Feasibility and safety of alternating radioligand treatment. Started Nov 2024; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetanradium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59548.